We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Cell Culture Technique Leads to Tailor-Made Cancer Treatments

By LabMedica International staff writers
Posted on 04 Jan 2015
A novel in situ capture and culture methodology has been developed for ex vivo expansion of circulating tumor cells (CTCs) using a three dimensional co-culture model, simulating a tumor microenvironment to support tumor development.

The potential utility of CTCs to guide clinical care in oncology patients has gained momentum with emerging micro- and nano-technologies and tumor progression and metastasis depends both on enumeration and on obtaining sufficient numbers of CTCs for downstream assays.

Scientists at the University of Michigan (Ann Arbor, MI, USA) developed the capture and culture process with a microfluidic chip device that captures cancer cells as a blood sample is pumped across it. More...
The team used a chip made of polydimethylsiloxane on a 1-inch by 3-inch glass slide. They covered the chip with microscopic posts that slow and trap cells, then coated it with antibodies that bind to the cancer cells.

Blood drawn from early lung cancer patients was flowed through the CTC-capture device at a flow rate of 1 mL/hour for 1 mL total for each device. After the cancer cells were captured on the chip, the team pumped in a growth medium mixture. They also added cancer-associated fibroblast cells. This created a three-dimensional environment that closely mimics the conditions inside the body of a cancer patient. After capture, cells also were fixed and immunofluorescently stained with labelled antibodies. The devices were scanned using a programmed inverted fluorescence microscope (Nikon, Melville, NY, USA). Positive and negative cells were designated as CTCs depending on the staining and enumerated.

The investigators used many other techniques including 3-D spheroid assays, invasion assays, sequencing, and real time polymerase chain reaction, (RT-PCR) which were analyzed on the ABI 7900HT instrument (Applied Biosystems; Foster City, CA; USA). After the cancer cells were captured on the chip, the team pumped in a mixture of collagen and Matrigel growth medium. The captured cancer cells prospered in the mixture, reproducing additional cells in 73% of tested samples. It was a dramatic improvement over earlier methods, which studied later-stage cancer patients and saw success rates of only around 20%.

Max S. Wicha, MD, distinguished professor of oncology, and coauthor of the study said, “The technology can be applied to most cancers, including breast, lung, pancreatic and others. It could enable doctors to follow the progression of each patient's disease much more closely. Cancer cells change constantly and they can quickly develop resistance to a given treatment. A device like this will enable us to follow the cancer's progression in real time. If a cancer develops resistance to one therapy, we'll be able to quickly change to a different treatment.” The study was published on December 1, 2014, in the journal Oncotarget.

Related Links:

University of Michigan  
Nikon
Applied Biosystems



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Chromogenic Culture System
InTray™ COLOREX™ ECC
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.